Wednesday, June 10, 2026
🇺🇸 FDA

pharma · Alopecia areata · Multiple myeloma

First Biotech (Australia)

Pfizer Australia Pty Ltd

First Biotech (Australia) clinical programs — 31 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
Norwest House, 710 Collins Street, Melbourne, VIC 3008, AU HQ
2017 Founded
2 Employees
TGA registrant Type
Company details
Status
Public
HQ
Norwest House, 710 Collins Street, Melbourne, VIC 3008, AU
Founded
2017
Employees
2
Programs
126
Drugs
208
Patents
0
Official website ↗ All projects Drug pipeline News & analysis
Intelligence · Clinical Programs

First Biotech (Australia) projects

31 ClinicalTrials.gov programs sponsored by First Biotech (Australia).

First Biotech (Australia) has 31 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

31 programs

Clinical programs

  1. A5481092

    Pfizer Australia Pty Ltd

    recurrent/refractory Ewing sarcoma, recurrent or refractory neuroblastoma

    phase 2 small molecule active

    1 trial

  2. B1791094

    Pfizer Australia Pty Ltd

    EROSIVE ESOPHAGITIS

    phase 2 small molecule active

    1 trial

  3. B1931036

    Pfizer Australia Pty Ltd

    Acute Lymphoblastic Leukemia (ALL)

    phase 2 small molecule active

    1 trial

  4. B7981118

    Pfizer Australia Pty Ltd

    CHRONIC SPONTANEOUS URTICARIA

    phase 2 small molecule active

    1 trial

  5. B7981119

    Pfizer Australia Pty Ltd

    HIDRADENITIS SUPPURATIVA

    phase 2 small molecule active

    1 trial

  6. C1131003

    Pfizer Australia Pty Ltd

    Primary immune thrombocytopenia

    phase 2 small molecule active

    1 trial

  7. C3601010

    Pfizer Australia Pty Ltd

    Sepsis, Suspected or Confirmed Infections Due to Gram-Negative Pathogens Requiring Intravenous Antibiotic Treatment, Complicated Urinary Tract Infection, Blood Stream Infection, Hospital-acquired pneumonia or ventilator-associated pneumonia, Complicated Intra-abdominal Infection

    phase 2 small molecule active

    1 trial

  8. C3651003

    Pfizer Australia Pty Ltd

    Cancer cachexia

    phase 2 small molecule active

    1 trial

  9. C3651011

    Pfizer Australia Pty Ltd

    Heart failure

    phase 2 small molecule active

    1 trial

  10. C4161001

    Pfizer Australia Pty Ltd

    Breast Cancer, Ovarian Cancer, SCLC (Part 1 also had TNBC and NSCLC)

    phase 2 small molecule active

    1 trial

  11. C4221008

    Pfizer Australia Pty Ltd

    Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  12. C4221022

    Pfizer Australia Pty Ltd

    MSI-H/dMMR metastatic colorectal cancer

    phase 2 small molecule active

    1 trial

  13. C4221023

    Pfizer Australia Pty Ltd

    Metastatic or unresectable locally advanced BRAF V600E/K mutation positive melanoma

    phase 2 small molecule active

    1 trial

  14. C4391025

    Pfizer Australia Pty Ltd

    HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE BREAST CANCER

    phase 2 small molecule active

    1 trial

  15. C4531002

    Pfizer Australia Pty Ltd

    Moderate-Severe Atopic Dermatitis

    phase 2 other active

    1 trial

  16. C4531029

    Pfizer Australia Pty Ltd

    Moderate-to-severe Asthma

    phase 2 other active

    1 trial

  17. C4921003

    Pfizer Australia Pty Ltd

    Heart failure

    phase 2 small molecule active

    1 trial

  18. C4971006

    Pfizer Australia Pty Ltd

    Relapsed/Refractory Diffuse Large B Cell Lymphoma

    phase 2 small molecule active

    1 trial

  19. C5041018

    Pfizer Australia Pty Ltd

    Ulcerative Colitis

    phase 2 small molecule active

    1 trial

  20. C5541010

    Pfizer Australia Pty Ltd

    Obesity, Overweight

    phase 2 small molecule active

    1 trial

  21. C6231002

    Pfizer Australia Pty Ltd

    Atopic Dermatitis

    phase 2 small molecule active

    1 trial

  22. C6461008

    Pfizer Australia Pty Ltd

    ADVANCED OR METASTATIC RENAL CELL CARCINOMA

    phase 2 small molecule active

    1 trial

  23. C6461013

    Pfizer Australia Pty Ltd

    Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma

    phase 2 small molecule active

    1 trial

  24. CT7001, PF-07850327 round

    Pfizer Australia Pty Ltd

    Advanced or Metastatic Breast Cancer

    phase 2 small molecule active

    1 trial

  25. Disitamab Vedotin

    Pfizer Australia Pty Ltd

    HER2 Expressing Advanced Breast Cancer

    phase 2 small molecule active

    1 trial

  26. ELRANATAMAB

    Pfizer Australia Pty Ltd

    Multiple myeloma

    phase 2 small molecule active

    1 trial

  27. FULVESTRANT, LETROZOLE

    Pfizer Australia Pty Ltd

    HR-positive HER2-negative metastatic/advanced BC

    phase 2 small molecule active

    1 trial

  28. LETROZOLE, FULVESTRANT

    Pfizer Australia Pty Ltd

    Part 2A, 2B, 2C & 2E HR-positive /HER2-negative breast cancer, Part 1F Prostate cancer, Part 2D mCRPC, Part 1A/Part 1D/Part1E Breast cancer, NSCLC, prostate, CRC, liposarcoma, or tumors with previously confirmed CDK4 or CCND1 amplification., Part 1B &1C HR-positive/HER2-negative breast cancer

    phase 2 small molecule active

    1 trial

  29. PF-07850327 round

    Pfizer Australia Pty Ltd

    ADVANCED OR METASTATIC BREAST CANCER

    phase 2 small molecule active

    1 trial

  30. PF-07868489

    Pfizer Australia Pty Ltd

    Pulmonary Arterial Hypertension

    phase 2 small molecule active

    1 trial

  31. Sigvotatug vedotin, PF-08634404

    Pfizer Australia Pty Ltd

    Advanced Solid Tumors

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does First Biotech (Australia) have?

31 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.